BGMS

Company Overview — What Does Cyclacel Pharmaceuticals, Inc. Do?

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuticals, Inc. (BGMS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Spiro Rombotis and employs approximately 14 people, headquartered in Berkeley Heights, New Jersey. With a market capitalization of $5M, BGMS is one of the notable companies in the Healthcare sector.

Cyclacel Pharmaceuticals, Inc. (BGMS) Stock Rating — Avoid (April 2026)

As of April 2026, Cyclacel Pharmaceuticals, Inc. receives a Avoid rating with a composite score of 20.7/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.BGMS ranks #3,985 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cyclacel Pharmaceuticals, Inc. ranks #688 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BGMS Stock Price and 52-Week Range

Cyclacel Pharmaceuticals, Inc. (BGMS) currently trades at $0.93. The stock lost $0.08 (7.9%) in the most recent trading session. Recent trading volume was 394K shares, suggesting relatively thin trading activity.

Is BGMS Overvalued or Undervalued? — Valuation Analysis

Cyclacel Pharmaceuticals, Inc. (BGMS) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.85x, versus the sector average of 2.75x. The price-to-sales ratio is 63.69x, compared to 1.66x for the average Healthcare stock.

At current multiples, Cyclacel Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cyclacel Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Cyclacel Pharmaceuticals, Inc. (BGMS) earns a quality factor score of 11/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -63.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -53.1% versus the sector average of -33.1%.

On a margin basis, Cyclacel Pharmaceuticals, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -11497.3% (sector: -66.1%). Net profit margin stands at -10394.9%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BGMS Debt, Balance Sheet, and Financial Health

Cyclacel Pharmaceuticals, Inc. has a debt-to-equity ratio of 20.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.70x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $4M.

BGMS has a beta of 8.99, meaning it is more volatile than the broader market — a $10,000 investment in BGMS would be expected to move 799.0% more than the S&P 500 on any given day. The stability factor score for Cyclacel Pharmaceuticals, Inc. is 5/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Cyclacel Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cyclacel Pharmaceuticals, Inc. reported revenue of $91,000 and earnings per share (EPS) of $-6.45. Net income for the quarter was $-4M. Gross margin was 100.0%. Operating income came in at $-10M.

In FY 2025, Cyclacel Pharmaceuticals, Inc. reported revenue of $747,000 and earnings per share (EPS) of $-6.45. Net income for the quarter was $-3M. Revenue grew 768.6% year-over-year compared to FY 2024. Operating income came in at $-8M.

In Q3 2025, Cyclacel Pharmaceuticals, Inc. reported revenue of $81,000 and earnings per share (EPS) of $-1.31. Net income for the quarter was $-988,000. Revenue grew 710.0% year-over-year compared to Q3 2024. Operating income came in at $-992,000.

In Q2 2025, Cyclacel Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.98. Net income for the quarter was $-1M. Operating income came in at $-1M.

Over the past 8 quarters, Cyclacel Pharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $91,000. Investors analyzing BGMS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BGMS Dividend Yield and Income Analysis

Cyclacel Pharmaceuticals, Inc. (BGMS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BGMS Momentum and Technical Analysis Profile

Cyclacel Pharmaceuticals, Inc. (BGMS) has a momentum factor score of 46/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 13/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

BGMS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cyclacel Pharmaceuticals, Inc. (BGMS) ranks #688 out of 838 stocks based on the Blank Capital composite score. This places BGMS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BGMS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BGMS vs S&P 500 (SPY) comparison to assess how Cyclacel Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

BGMS Next Earnings Date

No upcoming earnings date has been announced for Cyclacel Pharmaceuticals, Inc. (BGMS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BGMS? — Investment Thesis Summary

The quantitative profile for Cyclacel Pharmaceuticals, Inc. suggests caution. The quality score of 11/100 flags below-average profitability. The value score of 10/100 indicates premium valuation. High volatility (stability score 5/100) increases portfolio risk.

In summary, Cyclacel Pharmaceuticals, Inc. (BGMS) earns a Avoid rating with a composite score of 20.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BGMS stock.

Related Resources for BGMS Investors

Explore more research and tools: BGMS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BGMS head-to-head with peers: BGMS vs AZN, BGMS vs SLGL, BGMS vs VMD.